Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9357959 | 0.89 | UPP1 (0.39) | UPP1ALDH1A1TSHR | |
| SCHEMBL9353768 | 0.89 | UPP1 (0.39) | UPP1 | |
| Hept SCHEMBL384288 | 0.89 | UPP1 (0.48) | UPP1ALDH1A1TSHRHPGD | |
| SCHEMBL9353642 | 0.89 | DHFR (0.41) | UPP1DAONOTUM | |
| SCHEMBL9353855 | 0.86 | SMN1; SMN2 (0.38) | UPP1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9851436 | 0.82 | UPP1 (0.37) | UPP1 | |
| SCHEMBL7219945 | 0.82 | ALDH1A1 (0.39) | ALDH1A1TSHRTP53HPGDSMN1; SMN2 | |
| SCHEMBL29184178 | 0.81 | UPP1 (0.42) | UPP1DAOALDH1A1 | |
| SCHEMBL9353681 | 0.80 | HPGD (0.38) | UPP1ALDH1A1HPGD | |
| Hept SCHEMBL1732034 | 0.79 | UPP1 (0.40) | UPP1ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| CN-111163783-A | Compositions and methods for inhibiting HIV-1 reverse transcriptase | 美国政府卫生与公众服务部 | 2020-05-15 | — | — | CN | claimed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | claimed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | claimed |
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | claimed |
| US-8513205-B2 | Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase | YALE UNIVERSITY (US) | 2013-08-20 | — | — | US | claimed |
| WO-2013056003-A2 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 2013-04-18 | — | — | WO | claimed |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | ANDERSON KAREN S (US) | 2011-12-22 | — | — | US | claimed |
| WO-2009126293-A2 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | YALE UNIVERSITY (US) | 2009-10-15 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-0371139-B1 | 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS | MITSUBISHI CHEM IND (JP) | 1994-10-12 | — | — | EP | claimed |
| US-5112835-A | 6-SUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING THE SAME AS ACTIVE INGREDIENT THEREOF | MITSUBISHI KASEI CORPORATION (JP) | 1992-05-12 | — | — | US | claimed |
| EP-0371139-A1 | 6-SUBSTITUTED ACYCLICPYRIMIDINE NUCLEOSIDE DERIVATIVES AND ANTIVIRAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENTS | Mitsubishi Chemical Corporation (JP) | 1990-06-06 | — | — | EP | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-0829476-B1 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | MITSUBISHI CHEM CORP (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0829476-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5461060-A | Antiretroviral activity | MITSUBISHI KASEI CORPORATION (JP) | 1995-10-24 | — | — | US | disclosed |
| EP-0420763-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | COMT, NNMT, PNMT | UPP1 414/4885DAO 1210/4885NOTUM 309/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | UPP1 3954/4885DAO 220/4885NOTUM 4044/4885 |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | NAMPT, NAPRT, DNTT | UPP1 823/4885DAO 940/4885NOTUM 1048/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | UPP1 2740/4885DAO 2014/4885NOTUM 3807/4885 |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | UPP1 309/4885DAO 1331/4885NOTUM 219/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | UPP1 605/4885DAO 670/4885NOTUM 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.